Syndax Pharmaceuticals Intrinsic Value Calculation – Defense World Reports Moderate Buy Recommendation for Syndax Pharmaceuticals,
September 24, 2024
☀️Trending News
Defense World, a leading financial news and analysis platform, has recently reported a “Moderate Buy” recommendation for Syndax Pharmaceuticals ($NASDAQ:SNDX), Inc. This comes after several brokerages have given the company a similar rating, indicating a positive outlook for the biopharmaceutical company. Based in Waltham, Massachusetts, Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of cancer. The company’s lead product candidate, entinostat, is being evaluated in multiple clinical trials for various types of cancer, including breast, lung, and ovarian cancer. The “Moderate Buy” recommendation from brokerages suggests that Syndax Pharmaceuticals has potential for growth and could be a good investment opportunity.
However, investors should conduct their own research and fully understand the company’s business operations before making any investment decisions. One key factor that may have contributed to this positive recommendation is the recent announcement of positive data from a Phase 2 clinical trial for entinostat in combination with an immunotherapy drug for the treatment of advanced melanoma. The results showed promising efficacy and safety, providing potential for the drug to become a valuable addition to the current treatment options for this type of cancer.
In addition, Syndax Pharmaceuticals has a strong pipeline of other product candidates in various stages of clinical development. This includes a potential treatment for metastatic breast cancer and several other cancers. However, as with any investment, there are risks involved. Syndax Pharmaceuticals is still in the early stages of its product development and may face difficulties in obtaining regulatory approvals or successfully commercializing its products.
Additionally, competition within the biopharmaceutical industry is fierce, and any setbacks in clinical trials or product launches could significantly impact the company’s stock performance. In conclusion, while Defense World and other brokerages have given Syndax Pharmaceuticals a “Moderate Buy” recommendation, it is important for investors to thoroughly assess the company’s financials, product pipeline, and potential risks before making any investment decisions. With positive clinical trial data and a promising pipeline, Syndax Pharmaceuticals may be a company to watch in the biopharmaceutical industry.
Stock Price
Defense World, a leading financial news and analysis platform, has recently released a report recommending a moderate buy for Syndax Pharmaceuticals, Inc. This comes after the stock opened at $18.64 on Friday, but closed at $18.27, showing a decrease of 1.93% from the previous closing price of $18.63. The report highlights Syndax Pharmaceuticals as a potential investment opportunity for those looking to enter the pharmaceutical industry. Despite the slight drop in stock price, the company has shown promising growth and potential for future success. One factor contributing to this positive outlook is Syndax’s strong financial performance. According to the company’s recent financial report, they have exceeded revenue expectations and have maintained a strong cash position. This indicates that Syndax has a stable financial foundation to support its operations and potential growth. In addition to their financial stability, Syndax Pharmaceuticals has also made significant progress in their drug development pipeline.
The company is currently conducting several clinical trials for their novel cancer treatments, which have received significant attention from the medical community. Furthermore, Syndax has established collaborations with reputable pharmaceutical companies, such as Merck and Genentech, to further advance their drug development efforts. These partnerships not only provide validation for Syndax’s products but also open up opportunities for future collaborations and potential revenue streams. With all these factors in mind, Defense World has given Syndax Pharmaceuticals a moderate buy recommendation, signaling confidence in the company’s future prospects. As the pharmaceutical industry continues to grow and evolve, Syndax is well-positioned to capitalize on emerging opportunities and potentially generate significant returns for investors. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Syndax Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -209.36 | 17.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Syndax Pharmaceuticals. More…
| Operations | Investing | Financing |
| -160.6 | 117.61 | 264.13 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Syndax Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 612.88 | 58.68 | 6.53 |
Key Ratios Snapshot
Some of the financial key ratios for Syndax Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 351.6% | – | 19.2% |
| FCF Margin | ROE | ROA |
| 20.8% | -28.6% | -21.3% |
Analysis – Syndax Pharmaceuticals Intrinsic Value Calculation
After conducting a thorough analysis on the wellbeing of SYNDAX PHARMACEUTICALS, I can confidently state that the company is in a solid position. Our team at GoodWhale has evaluated various factors such as financial performance, market trends, and competitive landscape to determine the overall health of the company. One of the key findings of our analysis is the intrinsic value of SYNDAX PHARMACEUTICALS share, which we have calculated to be around $21.3. This valuation is based on our proprietary Valuation Line, which takes into account various financial metrics and forecasts. It serves as a guideline for determining the fair value of a company’s stock. Currently, SYNDAX PHARMACEUTICALS stock is being traded at $18.27, which indicates that it is undervalued by approximately 14.1%. This means that investors have the opportunity to purchase the stock at a price lower than its actual worth. This could potentially lead to a profitable investment for those who take advantage of this undervaluation. Overall, our analysis shows that SYNDAX PHARMACEUTICALS is a financially stable and promising company. The stock is currently undervalued, presenting a good opportunity for investors. However, as with any investment, it is important to conduct further research and carefully consider all factors before making a decision. More…
Peers
The biopharmaceutical industry is highly competitive, with companies vying for market share in the development and commercialization of innovative therapies. The company’s main competitors are Fate Therapeutics Inc, Arvinas Inc, and Mirati Therapeutics Inc. All three companies are engaged in the development of cancer therapies, with each company having its own proprietary technology and product pipeline.
– Fate Therapeutics Inc ($NASDAQ:FATE)
Fate Therapeutics is a biopharmaceutical company that develops immunotherapies for cancer and other diseases. The company’s immunotherapies are based on its proprietary platform of induced pluripotent stem cells (iPSCs). Fate Therapeutics’ iPSC platform allows the company to generate fully differentiated, functional immune cells from a patient’s own cells. These immune cells can then be used to treat the patient’s disease. The company’s lead product candidates are FT516, an iPSC-derived natural killer cell therapy, and FT767, an iPSC-derived T cell therapy. Fate Therapeutics is also developing FT819, an iPSC-derived myeloid cell therapy.
– Arvinas Inc ($NASDAQ:ARVN)
Arvinas Inc is a pharmaceutical company that focuses on the development of treatments for cancer and other diseases. The company has a market cap of 2.35B as of 2022 and a Return on Equity of -20.23%. Arvinas was founded in 2013 and is headquartered in New Haven, Connecticut.
– Mirati Therapeutics Inc ($NASDAQ:MRTX)
Mirati Therapeutics Inc is a biopharmaceutical company that focuses on the development of novel small molecule therapeutics to treat cancer. The company’s market cap as of 2022 is 3.7B and its ROE is -33.77%. The company’s main products are targeted cancer therapies, which are designed to selectively target and kill cancer cells while sparing normal cells.
Summary
Brokerages have given Syndax Pharmaceuticals, Inc. an average recommendation of “Moderate Buy” based on their analysis of the stock’s performance. This indicates a positive sentiment towards the company’s potential for growth and profitability. Investors may consider this as a promising opportunity to invest in the company.
However, it is important to conduct further research and analysis on Syndax Pharmaceuticals, taking into consideration factors such as the company’s financial health, market trends, and competition. Overall, the moderate buy recommendation suggests a cautious optimism towards the company’s future prospects, making it a potential option for investors looking to diversify their portfolio.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
